Incidence of breast cancer and methylation of PCDH gene: a single ratio meta analysis of single rate

IntroductionBreast cancer presents one of the highest rates of prevalence. With the development of genetics and biotechnology, we have learned that the occurrence and development of many cancers are closely related to abnormal gene expression. At present, some pieces of literature have reported that there may be a correlation between the expression of PCDH and the occurrence of breast cancer.Therefore, we selected some loci from PCDH gene to explore the correlation between the methylation of PCDH gene and breast cancer.Material and methodsThis research is a systematic review and critical appraisal, make a meta-analysis of prospective and retrospective cohort study. Research was conducted through computer Science, Wanfang and Chinese knowledge network databases PubMed, Embase and Network. In a literature search, seven cohort studies were identified. This I2 statistic is used to quantify heterogeneity. A fixed effect model was used to synthesize the results. Regression tests of linear funnel plot asymmetry were used to estimate potential publication bias.ResultsThe methylation rate of PCDH gene in breast cancer with lymph node metastasis was 75%, and that in breast cancer without lymph node metastasis was 70%. The methylation rate of PCDH gene was 75% in breast cancer group with high expression of the Ki-67 gene and 71% in breast cancer group with low expression of Ki-67 gene.ConclusionsAccording to previous studies, the positive rate of methylation of PCDH gene in breast cancer tissues is higher than that in adjacent tissues, and there is no obvious statistical difference in the correlation between lymphatic metastasis and Ki-67.

Download Full-text

Body mass index increases the lymph node metastasis risk of breast cancer: a dose-response meta-analysis with 52904 subjects from 20 cohort studies

BMC Cancer ◽

10.1186/s12885-020-07064-0 ◽

2020 ◽

Vol 20 (1) ◽

Author(s):

Junyi Wang ◽

Yaning Cai ◽

Fangfang Yu ◽

Zhiguang Ping ◽

Li Liu

Keyword(s):

Breast Cancer ◽

Body Mass Index ◽

Lymph Node ◽

Lymph Node Metastasis ◽

Cohort Studies ◽

Body Mass ◽

Dose Response ◽

Meta Analysis ◽

Node Metastasis

Download Full-text

Discussion of relationships among changes of pathological indicators, postoperative lymphedema of the upper limb, and prognosis of patients with breast cancer

Bioscience Reports ◽

10.1042/bsr20190231 ◽

2019 ◽

Vol 39 (4) ◽

Author(s):

Xiping Zhang ◽

Binbin Tang ◽

Dehong Zou ◽

Hongjian Yang ◽

Enqi Qiao ◽

...

Keyword(s):

Breast Cancer ◽

Lymph Node ◽

Lymph Node Metastasis ◽

Upper Limb ◽

Pathologic Complete Response ◽

Complete Response ◽

Expression Level ◽

Ki 67 ◽

Node Metastasis ◽

Ptnm Stage

Abstract Objectives: The present study aimed to discuss the impacts of changes to pathological indicators of patients with breast cancer upon the incidence of postoperative lymphedema of the upper limb and prognosis. Methods: 2597 female patients with breast cancer who received surgical treatment in our hospital were enrolled in the present study to evaluate the incidence of these patients’ postoperative lymphedema of the upper limb. Results: For patients with breast cancer, the incidence of postoperative lymphedema of the upper limb was related to T stage of breast cancer, lymph node metastasis, the number of metastatic lymph nodes, pTNM stage, and pathological types of breast cancer (P<0.05). Lymph node metastasis was an independent risk factor of lymphedema of the upper limb; lymph node metastasis and Ki-67 expression level were independent factors that impacted pathologic complete response rate of neoadjuvant chemotherapies. Patients’ mortality was correlated to pathological and molecular subtypes, Ki-67 expression level, ER expression level, PR expression level, and pTNM stage (P<0.05), among which the pTNM stage, Ki-67 expression level, and PR expression level were independent factors that affected prognosis of patients with breast cancer. Conclusion: Patients with lymph node metastasis were more prone to lymphedema of the upper limb, while it was easier for those whose Ki-67 expression level was high and who were not subject to lymph node metastasis to get a pathological complete response after receiving neoadjuvant chemotherapies. The prognosis was poorer among patients whose progesterone receptors were negative and Ki-67 expression levels were high at the advanced pTNM stage.

Download Full-text

Prognosis assessment of CD44+/CD24- in Breast Cancer Patients: a systematic review and meta-analysis

10.21203/rs.3.rs-318997/v1 ◽

2021 ◽

Author(s):

Jingjing Gu ◽

Dandan Chen ◽

Zhiqiang li ◽

Yongliang Yang ◽

Zhaoming Ma ◽

...

Keyword(s):

Breast Cancer ◽

Lymph Node ◽

Lymph Node Metastasis ◽

Cancer Patients ◽

Distant Metastasis ◽

Tumor Size ◽

Meta Analysis ◽

Breast Cancer Patients ◽

Clinical Prognosis ◽

Node Metastasis

Abstract Purpose: This meta-analysis investigated the relationships between the CD44+/CD24- phenotype and tumor size, lymph node metastasis, distant metastasis, disease-free survival (DFS), and overall survival (OS) in 8036 postoperative breast cancer patients enrolled in 23 studies.Methods: A literature search of PubMed, Medline, Cochrane, Embase, and PMC was conducted to identify eligible studies. The combined odds ratios (ORs) and 95% confidence intervals (95%CIs) were analyzed to evaluate the relationships between the CD44+/CD24- phenotype and the pathological and biological characteristics of breast cancer patients, and the combined hazard ratios (HRs) and 95% CIs were calculated to evaluate the relationships between CD44+/CD24- and DFS and OS of breast cancer petients using Stata12.0 software.Results: The CD44+/CD24- phenotype were not related to the tumor size (tumor size > 2.0 cm vs ≤ 2.0 cm, combined OR = 0.98, 95%CI: 0.68–1.34, p = 0.792) and didn’t promote lymph node metastasis (lymph node metastasis vs. no lymph node metastasis, combined OR = 0.94, 95% CI: 0.71–1.26, p = 0.692) and distant metastasis (distant metastasis vs no distant metastasis, combined OR = 3.88, 95% CI: 0.93–16.24, p = 0.064). The CD44+/CD24- phenotype was negatively correlated with postoperative DFS (HR = 1.67, 95% CI: 1.35–2.07, p <0.00001) and OS (combined HR = 1.52, 95%CI: 1.21–1.91, p = 0.0004).Conclusion: These results suggested expression of the CD44+/CD24- phenotype can be used as a reliable indicator of clinical prognosis and a potential therapeutic targets in breastcancer patients.

Download Full-text